Recurrent Nasopharyngeal Carcinoma Clinical Trials

9 recruiting

Frequently Asked Questions

Common questions about Recurrent Nasopharyngeal Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Stage IV Nasopharyngeal Carcinoma AJCC v8Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal Carcinoma
National Cancer Institute (NCI)156 enrolled77 locationsNCT06029270
Recruiting
Phase 2

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Stage IV Nasopharyngeal Carcinoma AJCC v8Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal Carcinoma
National Cancer Institute (NCI)50 enrolled92 locationsNCT05904080
Recruiting
Not Applicable

Proton Therapy for Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma
Guangzhou Concord Cancer Center52 enrolled2 locationsNCT07412314
Recruiting
Phase 3

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University176 enrolled7 locationsNCT06228079
Recruiting
Phase 3

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University154 enrolled7 locationsNCT06235203
Recruiting
Phase 3

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University212 enrolled12 locationsNCT03907826
Recruiting
Phase 2

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University100 enrolled7 locationsNCT05011227
Recruiting
Phase 2

Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC

Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University77 enrolled8 locationsNCT05350891
Recruiting
Phase 3

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma
Cancer Hospital of Guangxi Medical University204 enrolled1 locationNCT04376866